Comprehensive Smoking Education Act

BioAdaptives, Inc. Introduces PrimiSleep™, An Advanced Sleep-Aid Designed to Harmonize with the Body's Unique Circadian Rhythm, Delivering Gentle, Sustained, Restorative Sleep With No "Hangover"

Retrieved on: 
Thursday, July 7, 2022
Memory, OTC, Horse, Adult, Sound, Traditional Chinese medicine, COVID, GLOBE, Relaxation, Exercise, Company, Nutrient, U.S. Securities and Exchange Commission, Obesity, Food, Private Securities Litigation Reform Act, Comprehensive Smoking Education Act, Fatigue, Centers for Disease Control and Prevention, Sleep, Health, Dog, SEC, Hypertension, Human, Animal, Risk factor, Infection, Food and Drug Administration, Center, REM, Security (finance), Cognition, Grammatical mood, Pharmaceutical industry

LAS VEGAS, NV, July 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT), is pleased to announce the launch of a new, anti-stress, all-natural product, PrimiSleep™, specifically designed to induce relaxation and restful, continuous sleep. Comprehensively developed and test-marketed, this advanced formulation is based on Traditional Chinese Medicine and Ayurvedic Culture in response to a growing demand for an effective natural sleep supplement without the commonly associated “hangover” effect.

Key Points: 
  • Clinical studies show that components of PrimiSleep promote a restorative sleep pattern with increased REM intervals known to be beneficial.
  • PrimiSleep is all-natural, does not contain pharmaceuticals, and has no reported adverse reactions or dependence concerns.
  • According to the Center for Disease Control , over 70 million Americans are currently suffering from chronic sleep problems.
  • Edward Jacobs, M.D., BioAdaptives' CEO, states, The average adult needs about 7- 8 hours of sleep per day to remain healthy and productive.

Quipt Announces Execution of LOI to Acquire Leader in Comprehensive Respiratory Care Within the Long-Term Care Setting With Approximately $14 Million in Annualized Revenue and $1 Million in Net Income

Retrieved on: 
Monday, November 22, 2021
Patient, Crime, Heart, International, Insurance, CEO, Review, Risk, Environment, Technology, Comprehensive Smoking Education Act, LOI, CPA Canada, Acquisition, Income, Company, Sleep, EBITDA, Hand, Depreciation, Mission statement, Human, TSX Venture Exchange, COVID-19, Legislation, Conditional sentence, Letter, Attack, Adjustment, GAAP, GLOBE, U.S. Securities and Exchange Commission, Oxygen, International Accounting Bulletin, IFRS, Fraud, Disease management, Calendar, Negotiation, Internet, NASDAQ, Method, Growth, Quality of life, Retail, Risk management

CINCINNATI, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce that it has executed a non-binding letter of intent (the “LOI”) dated November 22, 2021 to acquire an arm’s length private respiratory care company servicing seven states throughout the U.S. reporting unaudited trailing 12-month annual revenues of approximately $14 million, $1 million in net income, and positive Adjusted EBITDA (defined below).

Key Points: 
  • The target specializes in providing high-quality, comprehensive respiratory care to patients in the long-term care setting including ventilator management, equipment, oxygen and providing supplies.
  • The target also has a pulmonary rehabilitation service, which assists patients with an even wider variety of respiratory care issues.
  • The target services facilities in seven states throughout the United States, four of which would be new states for Quipt.
  • The acquisition would be expected to increase Quipts annual revenues by approximately $14 million and $1 million in net income before synergies.